irbesartan + placebo

ApprovedUNKNOWN

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Persistent Atrial Fibrillation

Conditions

Persistent Atrial Fibrillation

Trial Timeline

May 1, 2009 → May 1, 2010

NCT ID

NCT00613496

About irbesartan + placebo

irbesartan + placebo is a approved stage product being developed by Sanofi for Persistent Atrial Fibrillation. The current trial status is unknown. This product is registered under clinical trial identifier NCT00613496. Target conditions include Persistent Atrial Fibrillation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00613496	Approved	UNKNOWN	May 1, 2009	May 1, 2010	Persistent Atrial Fibrillation
NCT00265642	Phase 3	Completed	Oct 1, 2006	Nov 1, 2013	Hepatitis C, Chronic

Competing Products

20 competing products in Persistent Atrial Fibrillation

See all competitors

Product	Company	Stage	Hype Score
E7777 9 mcg/kg	Eisai	Phase 3	77
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution	Santen Pharmaceutical	Phase 2	52
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E	AstraZeneca	Phase 1	33
AZD0837 + VKA INR 2-3	AstraZeneca	Phase 2	52
AZD0837 + Aspirin	AstraZeneca	Phase 2	52
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	23
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone Acetate	Novartis	Phase 2	52
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + Placebo	Novartis	Approved	85
Certoparin	Novartis	Phase 3	77
Omalizumab + Placebo	Novartis	Phase 3	77
Rivastigmine	Novartis	Approved	85
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days	Novartis	Phase 2	52
Indacaterol + Placebo to Indacaterol	Novartis	Phase 2	52
Omalizumab + Placebo	Novartis	Approved	85
placebo + iv sildenafil	Pfizer	Phase 3	76
etanercept + placebo	Pfizer	Phase 2	51
Sildenafil	Pfizer	Phase 2	51
iloprost	Bayer	Pre-clinical	20
IV Remodulin + Placebo	United Therapeutics	Phase 2	49
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)	Glaukos	Phase 2	49

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved